The type 2 diabetes mellitus treatment market was valued at USD 86.08 Billion in 2024 driven by the rising incidence of type 2 diabetes and advancements in the clinical trials across the 8 major markets. It is expected to grow at a CAGR of 17.20% during the forecast period of 2025-2034 and attain a market value of USD 420.90 Billion by 2034.
Base Year
Historical Year
Forecast Year
The increasing prevalence of diabetes is a significant factor that is driving the market. It is leading to heightened demand for innovative treatments such as GLP-1 receptor agonists, SGLT2 inhibitors, and advancements in oral therapies aimed at improving patient adherence.
One of the major market trends includes affluent pharmaceutical companies (including Novo Nordisk and Eli Lilly) focusing on developing innovative therapies such as oral GLP-1 receptor agonists and weight-loss medications, further highlighting an escalating focus on metabolic disorders. These advancements enhance competition and broaden treatment accessibility within the market.
North America holds a leading position in the market, attributed to its robust healthcare infrastructure, significant research and development funding, and the presence of major industry players.
Type 2 diabetes mellitus (T2DM) is a persistent metabolic condition marked by insulin resistance and elevated blood sugar levels. The market for T2DM treatments is expanding due to the growing incidence of diabetes and the need for innovative therapeutic options. Key trends include the development of new oral GLP-1 receptor agonists and the integration of digital health solutions. With increasing investment in research and supportive regulatory frameworks, the global market for T2DM treatments is on track to substantial growth and innovation.
Increasing Type 2 Diabetic Population Propelling Market Growth
The rising prevalence of diabetes mellitus presents a significant opportunity for market growth. According to a Centers for Disease Control and Prevention report released in May 2024, approximately 38 million Americans, or roughly 1 in 10 individuals, are diagnosed with diabetes. As the prevalence of this chronic condition continues to escalate, there is an increasing demand for innovative medications, continuous glucose monitoring devices, and telehealth solutions tailored for diabetes care. Consequently, pharmaceutical companies, medical device manufacturers, and digital health startups are poised to experience substantial market expansion, driven by the urgent need for effective management strategies and enhanced patient support systems.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Share by Route of Administration to Witness Substantial Market Growth
Based on the route of administration, the market is divided into oral, intravenous, and others. Among these, oral administration is expected to dominate the market as these medications are most commonly used to manage type 2 diabetes, especially for patients who are in the early stage of the disease. Oral medications, such as Metformin, Sulfonylureas, and DPP-4 Inhibitors, offer ease of use, and are widely available, making them a preferred choice for both patients and healthcare providers. Innovations such as oral GLP-1 receptor agonists further enhance this route’s appeal by combining efficacy with non-invasive delivery, addressing key market demands.
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan and India. Among these, the United States is expected to dominate the market share owing to a well-established infrastructure and the presence of major healthcare companies that are actively working to provide novel solutions. Further, significant funding to advance type 2 diabetes treatments is also expected the market growth in the region.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Novo Nordisk A/S, a prominent Danish multinational pharmaceutical company, is a prominent player in the market, with production operations spanning nine countries. The company is dedicated to enhancing treatment modalities for type 2 diabetes, evolving from traditional injection therapies to innovative oral formulations. Notably, Novo Nordisk has successfully transformed a synthetic variant of the glucagon-like peptide-1 (GLP-1) hormone renowned for its glucose-lowering properties into an oral tablet.
Sanofi SA, based in Paris, France, holds a significant presence in the pharmaceutical and healthcare landscape. In April 2024, Sanofi India introduced Soliqua, a once-daily injectable medication for diabetes management, available to consumers in India for INR 1850 per pen.
Pfizer Inc., headquartered in New York, United States, plays a critical role in advancing the pharmaceutical market through its comprehensive research initiatives and formidable market presence. The company is actively involved in the clinical development of danuglipron, an oral GLP-1 receptor agonist candidate, specifically designed for treating type 2 diabetes mellitus.
Merck & Co., an American multinational pharmaceutical company is a notable player in the industry, recognized for its extensive portfolio of prescription medications, vaccines, and biologic therapies. The company promotes public awareness regarding type 2 diabetes through its 'See it. Slow it. Stop it.' campaign, which informs individuals about the warning signs of the disease and inspires at-risk populations to adopt lifestyle modifications.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Eli Lilly and Company, AstraZeneca plc, Boehringer Ingelheim International GmbH, Takeda Pharmaceutical Company, and Roche.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share